Copyright 2008 Medical News Today Latest Cystic Fibrosis News From Medical News Today. http://www.medicalnewstoday.com/sections/cystic_fibrosis/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Thu, 03 Jul 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/113831.php Aradigm Corporation (OTCBB:ARDM) (the "Company") announced positive results from an open-label, two week efficacy and safety study of its once daily inhaled liposomal ciprofloxacin in patients with cystic fibrosis (CF). The study conducted at leading CF centers in Australia and New Zealand enrolled a total of 22 patients. Thu, 26 Jun 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/112767.php Mpex Pharmaceuticals, Inc. announced that it has initiated a Phase 2 clinical study with MP-376 for the treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis. MP-376 is Mpex's proprietary aerosol formulation of levofloxacin, an antibiotic that has potent activity against key bacterial pathogens, including Pseudomonas aeruginosa. Sat, 14 Jun 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/111303.php At the 31st European Cystic Fibrosis Society (ECFS) Annual Meeting in Prague, Czech Republic, researchers presented interim results from the first clinical trial of the investigational oral agent VX-770 in cystic fibrosis patients. Sat, 14 Jun 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/111262.php Transave, Inc., reported positive results from a Phase II clinical trial on its lead investigational drug, Arikace(TM) (liposomal amikacin for inhalation). The compound is being developed for the treatment of cystic fibrosis (CF) patients who have lung infections due to the bacterium Pseudomonas aeruginosa. Fri, 13 Jun 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/111067.php PTC Therapeutics, Inc. (PTC) announced promising new data from two studies of PTC124 in cystic fibrosis (CF). Wed, 14 May 2008 05:00:00 PDT http://www.medicalnewstoday.com/articles/107350.php Alabama has joined 39 other states and the District of Columbia in requiring that all newborns be screened for cystic fibrosis at birth. "We congratulate Alabama for initiating a newborn screening program for cystic fibrosis," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "More than 40 states are now screening for the disease. Mon, 05 May 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/106258.php The 13th annual Breathing Life Awards will be taking place on Wednesday 28th May at Hilton Metropole and televised on Sky Real Lives (Sky channel 253) on Sunday 1st June, 9.30pm. Hosted by Carol Smillie and Dr David Bull, the glitzy awards ceremony celebrates the outstanding achievement of inspiring people that have Cystic Fibrosis (CF), the UK's most common life-threatening inherited disease. Sun, 27 Apr 2008 18:00:00 PDT http://www.medicalnewstoday.com/articles/105201.php Scientists from the UK CF Gene Therapy Consortium funded by the Cystic Fibrosis Trust have overcome a major obstacle in their ground-breaking gene therapy programme for Cystic Fibrosis. Cystic Fibrosis (CF) is the UK's most common life-threatening inherited disease and is caused by a single defective gene. Mon, 21 Apr 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/104756.php The Alabama Department of Public Health in partnership with the cystic fibrosis centers at the University of Alabama at Birmingham, Children's Hospital of Alabama and the University of South Alabama announces further significant expansion of Alabama's newborn screening program. On April 21, Alabama will add cystic fibrosis to its panel of primary newborn screening tests. Mon, 14 Apr 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/103828.php During the Satellite Symposium 3: The Challenges of Lung Transplantation in Cystic Fibrosis (CF) at the International Society of Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, clinicians and researchers discussed some of the unique challenges in achieving excellent lung transplant outcomes in patients with CF. Sun, 13 Apr 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/103793.php A team of researchers led by University of Sunderland scientists has made a major breakthrough in the fight against a deadly hospital infection which kills tens of thousands of people every year. Experts have discovered a technique for the early detection of the superbug pseudomonas aeruginosa which particularly infects patients with cystic fibrosis. Sat, 12 Apr 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/103755.php During Wednesday's Satellite Symposium 3: The Challenges of Lung Transplantation in Cystic Fibrosis (CF) at the International Society of Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, clinicians and researchers discussed some of the unique challenges in achieving excellent lung transplant outcomes in patients with CF. Thu, 10 Apr 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/103441.php Illinois and Vermont have joined 37 other states and the District of Columbia in requiring that all newborns be screened for cystic fibrosis at birth. In addition, the Nevada Department of Health has decided to begin regular CF screening as well. Routine screening will be implemented when state lawmakers set an implementation date. Tue, 08 Apr 2008 07:00:00 PDT http://www.medicalnewstoday.com/articles/103200.php Dry airways may not only play a central role in the development of the in-herited lung disease cystic fibrosis, but also in much more common acquired chronic lung diseases such as asthma and smoker's lung, the ciga-rette smoke-induced chronic obstructive pulmonary disease (COPD). This is the conclusion reached by scientists at Heidelberg University Hospital under the direction of Assistant Professor Dr. Thu, 03 Apr 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/102599.php KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced the initiation of a Phase 1/2 clinical trial of KB001, a Humaneered™, high-affinity antibody fragment that KaloBios is developing for the treatment of P. aeruginosa infections. The trial is being conducted in conjunction with the Cystic Fibrosis Foundation and its affiliated organizations. Tue, 01 Apr 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/102247.php Responding to a study published in the New England Journal of Medicine, which concluded that lung transplants were harmful for children with cystic fibrosis, articles published in the latest issue of Pediatric Transplantation refute the conclusions and argue that the highly influential research was severely flawed. According to two rebuttals published in the acclaimed journal, the conclusions of the study on post-transplant survival rates led by Theodore G. Tue, 01 Apr 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/102242.php "Drug 'could aid cystic fibrosis'" is the headline on BBC News. The article says that "widely-used antidepressants could prevent infections which shorten the lives of many cystic fibrosis patients". The report is based on the findings from a study in mice which has shed further light on the biological processes involved in the changes to the lungs caused by the cystic fibrosis mutation. Lung infections are a major cause of death in people who have cystic fibrosis. Fri, 28 Mar 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/102015.php The Cystic Fibrosis Foundation has announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated. Fri, 28 Mar 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/101930.php The Cystic Fibrosis Foundation has announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated. Fri, 28 Mar 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/101966.php The Cystic Fibrosis Foundation announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated. Sat, 22 Mar 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/101394.php Thousands of people will be taking steps to cure Cystic Fibrosis (CF) this year by taking part in a series of sponsored walks across the UK. Great Strides, sponsored by Solvay Healthcare, is a worldwide initiative to get people walking to help see off CF. The sponsored walks aim to raise funds to help the 8,000 people with CF in the UK look forward to a brighter future and a longer and better quality of life. Wed, 19 Mar 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/101079.php The Cystic Fibrosis Foundation has announced the launch of a new $5 million initiative to enhance care for the growing adult CF population. The initiative, called the Program for Adult Care Excellence (PACE), will expand the scope of adult care programs for people with cystic fibrosis. The number of adults with cystic fibrosis continues to increase as life expectancy for the disease continues to rise. Wed, 19 Mar 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/101009.php New U of T research holds promise for developing innovative therapies against cystic fibrosis and may also serve as a model for future therapies against the HIV virus. Led by Professor Igor Stagljar, University of Toronto scientists have identified several compounds that block activity of a key protein (exoenzymeS or ExoS). Mon, 10 Mar 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/99946.php According to a report in the open-access journal PLoS Computational Biology, there is a specific molecular mechanism that could be responsible for the development of cystic fibrosis. The University of North Carolina at Chapel Hill researchers suggest better understanding of the disease may help to develop new corrective treatments. About 1 in 3000 children is born with cystic fibrosis (CF) in the US every year. Fri, 07 Mar 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/99824.php Cystic fibrosis is the most common genetic disease in Caucasians. The median lifespan for those with the disease is 36 years, and lung disease is the major cause of mortality. For years, scientists have studied cystic fibrosis using mice in which the cystic fibrosis gene was altered. However, mice do not develop lung disease like humans with cystic fibrosis.